Source: Frontiers in Immunology. Unidades: FCFRP, ICB, FMRP
Subjects: ENTEROPATIAS INFLAMATÓRIAS, COLITE ULCERATIVA, DOENÇA DE CROHN, INTERLEUCINA 10, INTERLEUCINA 6
ABNT
BASSO, Paulo José et al. Peroxisome proliferator-activated receptor alpha mediates the beneficial effects of atorvastatin in experimental colitis. Frontiers in Immunology, v. 12, p. 1-14, 2021Tradução . . Disponível em: https://doi.org/10.3389/fimmu.2021.618365. Acesso em: 31 out. 2024.APA
Basso, P. J., Sales-Campos, H., Nardini, V., Duarte-Silva, M., Alves, V. B. F., Bonfá, G., et al. (2021). Peroxisome proliferator-activated receptor alpha mediates the beneficial effects of atorvastatin in experimental colitis. Frontiers in Immunology, 12, 1-14. doi:10.3389/fimmu.2021.618365NLM
Basso PJ, Sales-Campos H, Nardini V, Duarte-Silva M, Alves VBF, Bonfá G, Rodrigues CC, Nunes BG, Chica JEL, Nomizo A, Cardoso CR de B. Peroxisome proliferator-activated receptor alpha mediates the beneficial effects of atorvastatin in experimental colitis [Internet]. Frontiers in Immunology. 2021 ; 12 1-14.[citado 2024 out. 31 ] Available from: https://doi.org/10.3389/fimmu.2021.618365Vancouver
Basso PJ, Sales-Campos H, Nardini V, Duarte-Silva M, Alves VBF, Bonfá G, Rodrigues CC, Nunes BG, Chica JEL, Nomizo A, Cardoso CR de B. Peroxisome proliferator-activated receptor alpha mediates the beneficial effects of atorvastatin in experimental colitis [Internet]. Frontiers in Immunology. 2021 ; 12 1-14.[citado 2024 out. 31 ] Available from: https://doi.org/10.3389/fimmu.2021.618365